Sex: U
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Patient do not have any allergies.  Concurrent medical conditions included Asthma. Concomitant products included BUPROPION HYDROCHLORIDE (WELLBUTRIN) for an unknown indication.   On 04-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Sep-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 25-May-2022 to 29-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: positive (Positive) Positive. In 2022, SARS-CoV-2 test: negative (Negative) had 2 negative tests, negative (Negative) had 2 negative tests and. In June 2022, SARS-CoV-2 test positive (Positive) with a positive result.         The patient was taking  other medications/products within 2 weeks of starting COVID-19 treatment.Patient started taking Paxlovid when tested positive for COVID. Patient have asthma. Patient started feeling better on day 6-7 also had 2 negative tests. On day10th patient's throat started hurting again, nasal congestion and chills. Patient tested for Covid and resulted positive. Device Date : 03Jun2022  Company comment: This spontaneous case concerns a patient (age and gender unspecified) with no relevant medical history, who experienced the unexpected non-serious AESI of Covid-19, nine months after receiving the 3rd dose of mRNA-1273 vaccine. The patient had received a course of Paxlovid (Nirmatrelvir + Ritonavir) for five days for Covid-19. Following this the patient had tested negative on two occasions. But, five days after completion of the course, the patient had recurrence of symptoms (throat pain, nasal congestion, and chills) and tested positive for SARS-CoV-2 test. The outcome was reported as not resolved. Details of symptoms, start date, clinical course, further investigation reports and treatment were not provided. Seven months prior to the third dose, the patient has received the two primary doses of mRNA-1273 vaccine. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a patient (age and gender unspecified) with no relevant medical history, who experienced the unexpected non-serious AESI of Covid-19, nine months after receiving the 3rd dose of mRNA-1273 vaccine. The patient had received a course of Paxlovid (Nirmatrelvir + Ritonavir) for five days for Covid-19. Following this the patient had tested negative on two occasions. But, five days after completion of the course, the patient had recurrence of symptoms (throat pain, nasal congestion, and chills) and tested positive for SARS-CoV-2 test. The outcome was reported as not resolved. Details of symptoms, start date, clinical course, further investigation reports and treatment were not provided. Seven months prior to the third dose, the patient has received the two primary doses of mRNA-1273 vaccine. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.